England to Review Rejection of Lilly Alzheimer’s Drug for NHS
England’s drug price regulator will have to reconsider its decision to rule out using Eli Lilly & Co.’s Alzheimer’s drug in the state-run National Health Service, following a successful appeal...
By Ashleigh Furlong · Bloomberg
England’s drug price regulator will have to reconsider its decision to rule out using Eli Lilly & Co.’s Alzheimer’s drug in the state-run National Health Service, following a successful appeal by the US drugmaker.